# Safety & Efficacy of EPO-018B for the Treatment of Anemia in Participants With ERSD Receiving Maintenance Hemodialysis

> **NCT02366325** · PHASE2 · UNKNOWN · sponsor: **Jiangsu Hansoh Pharmaceutical Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Chronic Renal Failure
- Anemia

## Interventions

- **DRUG:** EPO-018B

## Key facts

- **NCT ID:** NCT02366325
- **Lead sponsor:** Jiangsu Hansoh Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-07
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2015-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02366325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02366325, "Safety & Efficacy of EPO-018B for the Treatment of Anemia in Participants With ERSD Receiving Maintenance Hemodialysis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02366325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*